Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Benfotiamine (fat-soluble vitamin B1)

Benfotiamine (Fat-Soluble Vitamin B1) · also known as Benfotiamine, Fat-soluble vitamin B1, S-benzoylthiamine monophosphate

Benfotiamine is a fat-soluble precursor of vitamin B1. Taken orally, it can raise thiamine levels and support transketolase activity. In randomized human trials it did not consistently lower the AGEs that were measured, and there is no consistent evidence of a clinical anti-glycation benefit.

Typical dose: Typical doses are 150–300 mg/day, taken in the morning or at lunch. The randomized human anti-glycation trial used 900 mg/day, so its results cannot be extrapolated directly to this dose range.
Absorption and forms: Benfotiamine is fat-soluble. Taken orally, it can raise circulating thiamine and red blood cell thiamine diphosphate. Relative bioavailability varies with formulation, dose and the measure used, so the claim that it is “hundreds of times” more bioavailable should not be applied uncritically.

Clinical uses and human evidence

Peripheral neuropathy (numbness and tingling)

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Stracke 2008 · Exp Clin Endocrinol Diabetes · RCT · n=165 — Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study
  2. Ziegler 2026 · BMJ Open Diabetes Res Care · RCT · n=57 — Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study)

Age-related cognitive decline

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Gibson 2020 · J Alzheimers Dis · RCT · n=70 — Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial

Mechanisms of action

Blocking advanced glycation end products (AGEs) and protein cross-linking

★★★☆☆Mechanism evidence: grade A

After conversion to thiamine diphosphate, benfotiamine can support transketolase activity, shifting more glycolytic intermediates into the pentose phosphate pathway. Transketolase activity rose in a randomized human trial, but advanced glycation end products (AGEs) did not fall consistently.

References (2)
  1. Hammes et al. 2003 · Diabetic rat study: benfotiamine increased transketolase activity and reduced glycation-related damage
  2. Alkhalaf et al. 2012 · RCT: 900 mg/day raised thiamine status and transketolase activity, but did not consistently lower measured AGEs

Direct free radical trapping and chemical quenching

★☆☆☆☆Mechanism evidence: grade DSecondary target

In vitro, benfotiamine can directly scavenge superoxide at concentrations of about 0.5–1 mmol/L, but free drug exposure after usual oral doses is far below that level. A direct free-radical scavenging effect has not been established in humans.

References (1)
  1. 2015 cell and cell-free study · Benfotiamine can directly scavenge superoxide at experimental concentrations of about 0.5–1 mmol/L

Safety and drug interactions

Well tolerated at usual doses, except in the rare person with an allergy to thiamine compounds.
Open in the interactive app ›